WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES

Gelijkaardige items

• WCN25-843 FELZARTAMAB REDUCES aPLA2R Ab BY SELECTIVELY DEPLETING CD38+ PLASMA CELLS AND PLASMABLASTS, THE MAIN PATHOGENIC CELLULAR DRIVERS OF DISEASE IN PRIMARY MEMBRANOUS NEPHROPATHY (PMN)
  door: Donna Flesher, et al.
  Gepubliceerd in: (2025-02-01)
• WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
  door: Uptal Patel, et al.
  Gepubliceerd in: (2025-02-01)
• WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
  door: Jonathan Barratt, et al.
  Gepubliceerd in: (2025-02-01)
• WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
  door: Dmitrij Kollins, et al.
  Gepubliceerd in: (2025-02-01)
• WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
  door: Dmitrij Kollins, et al.
  Gepubliceerd in: (2025-02-01)